In this article, we will take a look at the best NASDAQ stocks under $10 to buy.
As retail participation in equity markets continues to expand, investor interest is increasingly shifting toward lower-priced stocks and companies outside the traditional mega-cap universe. Despite lower-priced stocks generally being associated with higher volatility, they often offer strong upside potential.
As outlined in Morningstar’s article “December 2025 US Stock Market Outlook: Where We See Investment Opportunities” by David Sekera, the Chief U.S. Market Strategist, small-cap stocks have outperformed in November. While the Morningstar US Small Cap Index surged 2.48%, its US Mid Cap Index rose merely 0.64% and its US Large Cap Index declined 0.05%. Thus, investing in leading companies doesn’t necessarily mean better returns.
In a Barron’s article titled “Cash Holdings Hit Record Lows as Investors Go Big on Stocks. What History Says Happens Next,” published on December 16, the author writes that investors all around the world are entering 2026 with the lowest levels of cash. As reported by Bank of America’s closely tracked survey of fund managers, investors are betting big on “stocks, commodities, and President Donald Trump’s ‘run it hot’ economic strategy.”
With this backdrop, we have compiled a list of the best NASDAQ stocks under $10 to buy. These stocks belong to a range of sectors, including healthcare, technology, and energy.
Our Methodology
For this article, we considered companies listed on the NASDAQ exchange with share prices below $10. From these stocks, we have selected those with a market capitalisation of more than $2 billion and upside potential of at least 20%. We then shortlisted the ten companies with the highest upside potential and ranked them in ascending order. We also included data on hedge fund holdings in these companies based on Insider Monkey’s database, as of Q3 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
10. ZoomInfo Technologies Inc. (NASDAQ:GTM)
Upside Potential as of December 15, 2025: 32.45%
On December 15, KeyBanc upgraded ZoomInfo Technologies Inc. (NASDAQ:GTM) to ‘Sector Weight’ from ‘Underweight’ without a price target, as reported by TheFly. This adjustment was part of the firm’s 2026 outlook, with the firm preferring small- and mid-cap software over large-cap software. According to KeyBanc, the company has moved past the worst of its down-market pressure and potential challenges from its private rivals.
The research firm views the company’s guidance strategy of delivering meaningful annual and quarterly earnings beats as intact, heading into 2026. KeyBanc highlights the company’s sustained commitment to share repurchases as a favorable point for stock performance. What’s even more interesting is that the firm expects that even with low-single-digit top-line growth, ZoomInfo Technologies Inc. (NASDAQ:GTM) is well-positioned to perform consistently relative to the firm’s coverage universe and the broader software sector next year.
During the latest earnings call, management emphasized the company’s unique footing in the market, noting that many of the “world’s fastest-growing and most innovative AI-native companies,” particularly Levelpath, Pano.ai, and Tilts, use ZoomInfo Technologies Inc. (NASDAQ:GTM) to “scale their sales teams and need data, signals, and workflow to scale in the enterprise.” Reaffirming this, Henry Schuck, the CEO and Founder, said,
“For 20 years, ZoomInfo has been the trusted source of truth for company and contact data. That foundation isn’t going away.”
ZoomInfo Technologies Inc. (NASDAQ:GTM) is a Washington-based provider of go-to-market intelligence and engagement platforms. Founded in 2007, the company serves a wide range of industries, including education, financial services, and telecommunications.
9. Melco Resorts & Entertainment Limited (NASDAQ:MLCO)
Upside Potential as of December 15, 2025: 42.54%
As of December 15, Melco Resorts & Entertainment Limited (NASDAQ:MLCO) has a rating of ‘Buy’ or equivalent from 69% of the analysts covering the stock. With a median price target of $11.38, the stock has an upside potential of 42.54%.
According to TheFly, BofA slightly lifted the price target on Melco Resorts & Entertainment Limited (NASDAQ:MLCO) to $9.50 from $9 on November 27, while maintaining a ‘Neutral’ rating on the stock. In line with management’s statement on the third-quarter earnings call to resume its quarterly dividend by year-end 2026, the analyst anticipates a dividend per ADS of 7c and 30c in FY26 and FY27, respectively.
During the last earnings call, management reaffirmed the company’s focus on introducing new initiatives to improve the quality of engagement with its customers. Melco Resorts & Entertainment Limited (NASDAQ:MLCO) plans to close two Mocha Clubs before heading into 2026 and relocate the gaming machines across its three properties in Macau. By the third quarter of 2026, the company expects to open the Countdown Hotel, which is currently being renovated. Once completed, this hotel will bring a unique experience to Macau and the region, said Lawrence Ho, the Chairman and CEO. He further added,
“We plan to simultaneously upgrade retail and food and beverage in this precinct of COD and continue to elevate the quality of our product offerings.”
Melco Resorts & Entertainment Limited (NASDAQ:MLCO) is a Hong Kong-based company specializing in casino gaming and resort facilities. Founded in 2004, the company operates City of Dreams, Altira Macau, Studio City, and Mocha Clubs, among others.
8. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Upside Potential as of December 15, 2025: 42.86%
As of December 15, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has a ‘Hold’ or equivalent rating from 71% of the analysts covering the stock. With a median price target of $6, the stock has an upside potential of 42.86%.
On December 9, Alec Stranahan from Bank of America Securities reaffirmed a ‘Hold’ rating on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), while setting a price target of $7, which suggests an upside potential of about 67%.
Just a day earlier, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) revealed its Phase 1b/2 TUPELO trial results for REC-4881, which is an experimental solution for familial adenomatous polyposis (FAP). The results showed that 75% of 12 evaluable patients demonstrated reductions in total polyp burden following 12 weeks of treatment with REC-4881 at 4 mg daily, reporting a median reduction of 43%.
These results were compared to natural history data, outlining that 87% of untreated FAP patients experience yearly increases in polyp burden. With no approved medical therapies as yet, FAP impacts as many as 50,000 individuals in the US and EU5 countries.
Following the findings, Gil Blum, an analyst at Needham, maintained a ‘Buy’ rating on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), with a price target of $8, on December 8.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a Utah-based clinical-stage biotechnology company specializing in the decoding of biology and chemistry. Founded in 2013, the company develops REC-994, REC-2282, and REC-4881, among others.
7. CCC Intelligent Solutions Holdings Inc. (NASDAQ:CCC)
Upside Potential as of December 15, 2025: 52.12%
As of December 15, CCC Intelligent Solutions Holdings Inc. (NASDAQ:CCC) has a ‘Buy’ or equivalent rating from around 80% of the analysts covering the stock. With a median price target of $11.50, the stock has 52.12% upside potential.
On December 12, Kirk Materne, an analyst at Evercore ISI, reaffirmed a ‘Buy’ rating on CCC Intelligent Solutions Holdings Inc. (NASDAQ:CCC), while setting a price target of $12. This reflects a potential upside of about 59%.
On the same day, CCC Intelligent Solutions Holdings Inc. (NASDAQ:CCC) announced the authorization of a new $500 million share repurchase program of the company’s outstanding common stock. This follows the existing $300 million accelerated share repurchase (ASR) program with Bank of America, which is backed by incremental term loans under its amended credit agreement. Under the terms, the company will initially receive about 33.2 million shares, reflecting nearly 80% of the anticipated total repurchase volume.
As stated by Githesh Ramamurthy, Chairman & CEO of CCC Intelligent Solutions Holdings Inc. (NASDAQ:CCC),
“Our strong balance sheet gives us the flexibility to continue to innovate for our customers and invest in the business while also delivering returns to shareholders.”
What’s more interesting is that CCC Intelligent Solutions Holdings Inc. (NASDAQ:CCC) is actively investing in the company to accelerate value creation, enhance go-to-market capabilities, strengthen client and partner relationships, and power its multisided network, as highlighted during the earnings call.
CCC Intelligent Solutions Holdings Inc. (NASDAQ:CCC) is an Illinois-based software-as-a-service (SaaS) company. Founded in 1980, the company is committed to “turning crucial moments into intelligent experiences.”
6. Peloton Interactive, Inc. (NASDAQ:PTON)
Upside Potential as of December 15, 2025: 56.80%
As of December 15, Peloton Interactive, Inc. (NASDAQ:PTON) has a ‘Hold’ rating from half of the analysts covering the stock. With a median price target of $9.80, the stock has an upside potential of 56.80%.
On December 10, Simeon Siegel from Guggenheim assumed coverage on Peloton Interactive, Inc. (NASDAQ:PTON) with a ‘Neutral’ rating, according to TheFly. The analyst believes the retail sector appears to be “structurally sick,” but “holiday brought the cheer,” adding that tariffs have been largely manageable so far and “most importantly and likely going unnoticed” is the fact that most of the firm’s coverage runs at, or near, its gross margin highs.
This follows a series of analyst revisions in November. On November 20, Ronald Josey from Citi trimmed the price target on Peloton Interactive, Inc. (NASDAQ:PTON) to $8.25 from $9.50, while keeping a ‘Neutral’ rating on the stock. According to TheFly, Citi lowered its subscriber forecasts for the company by 3% for the full year “to reflect greater churn.” Just a day earlier, Morgan Stanley lifted the price target on the company to $6.50 from $6, keeping an ‘Equal Weight’ rating on the stock, citing model changes from Q3 earnings.
Peloton Interactive, Inc. (NASDAQ:PTON) is a New York-based provider of fitness and wellness products and services. Incorporated in 2012, the company offers connected fitness products and Peloton App memberships, as well as leases Peloton Bike+ products.
5. VinFast Auto Ltd. (NASDAQ:VFS)
Upside Potential as of December 15, 2025: 68.78%
On December 15, the local unit chief executive told Reuters that VinFast Auto Ltd. (NASDAQ:VFS) will boost its investment in Indonesia to up to $1 billion. This announcement follows VinFast Indonesia’s inauguration of its first manufacturing plant in Indonesia, with an annual production capacity of 50,000 cars.
In light of this, the VinFast Indonesia CEO, Kariyanto Hardjosoemarto, said, “VinFast will continue to increase its investment to $1 billion, with an increase in production capacity to 350,000 per year,” adding that VinFast Auto Ltd. (NASDAQ:VFS) has already invested $300 million in the region.
He noted that the plant in Subang, West Java, recently began trial production and is anticipated to run at full capacity in the first quarter of 2026. While it depends on future demand, VinFast’s investment in Southeast Asia’s largest economy could surpass $1 billion, Kariyanto concluded.
Even on its earnings call, management highlighted the company’s focus on expanding its international footprint and announced a new vehicle platform for 2026, which has the potential to contribute approximately 70-80% to sales. Despite challenges, VinFast Auto Ltd. (NASDAQ:VFS) remains committed to international market growth, with an emphasis on achieving economies of scale through higher production.
VinFast Auto Ltd. (NASDAQ:VFS) is a Vietnamese company specializing in electric vehicles (EVs), e-scooters, and e-buses. Incorporated in 2017, the company operates through three segments: namely Car, E-scooters, and Ebus.
4. Telix Pharmaceuticals Limited (NASDAQ:TLX)
Upside Potential as of December 15, 2025: 110.14%
On December 15, RBC Capital assumed coverage on Telix Pharmaceuticals Limited (NASDAQ:TLX) with a Sector Perform rating and a price target of AUD17.00. The research firm notes that the company has successfully commercialized two diagnostic assets for prostate cancer and has substantial opportunities to expand indications.
Although Telix Pharmaceuticals Limited (NASDAQ:TLX) has a diverse range of pipeline assets that it’s working to commercialize, RBC expects earnings and free cash flow to remain essentially flat between fiscal years 2025 and 2027 as the company engages in R&D.
Earlier, on December 10, Telix Pharmaceuticals Limited (NASDAQ:TLX) announced a strategic clinical partnership with Varian to build applications integrating the company’s theranostic offering with external beam radiation therapy (EBRT). With an aim to accelerate radiation oncology treatments, the collaboration will initially focus on using PSMA-PET imaging for individuals undergoing prostate cancer radiotherapy.
Starting with PSMA imaging, the framework is designed to accommodate future expansion to Telix diagnostic candidates, including Zircaix and Pixclara, as well as other potential therapeutic radiopharmaceuticals. The collaboration is what the CEO and Managing Director, Dr. Christian Behrenbruch, described as “a transformative opportunity to bring precision imaging into the heart of radiation oncology.”
Overall, Telix Pharmaceuticals Limited (NASDAQ:TLX) is a consensus buy from the majority of the analysts covering the stock. The median price target of $18.14 translates to an upside potential of 110.14%.
Telix Pharmaceuticals Limited (NASDAQ:TLX) is an Australian commercial-stage biopharmaceutical company specializing in therapeutic and diagnostic radiopharmaceuticals. Founded in 2015, the company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
3. Aurora Innovation, Inc. (NASDAQ:AUR)
Upside Potential as of December 15, 2025: 187.08%
As of December 15, Aurora Innovation, Inc. (NASDAQ:AUR) has a ‘Buy’ rating from half of the analysts covering the stock. With a median price target of $12, the stock has an upside potential of 187.08%.
On December 9, George Gianarikas from Canaccord Genuity reaffirmed a ‘Buy’ rating on Aurora Innovation, Inc. (NASDAQ:AUR), while setting a $15 price target, which reflects a potential upside of about 259% from the current level. On the same day, Itay Michaeli, an analyst at TD Cowen, maintained a ‘Hold’ rating on the company and set a price target of $5.50.
In other news, Aurora Innovation, Inc. (NASDAQ:AUR) disclosed an agreement with Detmar Logistics to provide 24/7 autonomous transportation of proppants for a multinational oil and gas company on December 8. According to TheFly, with the deployment of the company’s second fleet of driverless trucks, scheduled for the second quarter of 2026, Detmar’s trips will transition to fully driverless operations.
Earlier on November 25, Christopher Urmson, Chief Executive Officer of Aurora Innovation, Inc. (NASDAQ:AUR), acquired 258,000 shares of Class A Common Stock at a weighted average price of $3.8784. Following the $1,000,627 investment, Urmson now directly holds 5,000,000 shares of the company’s stock.
Aurora Innovation, Inc. (NASDAQ:AUR) is a Pennsylvania-based self-driving technology company. Founded in 2017, the company is committed to developing Aurora Driver.
2. Fermi Inc. (NASDAQ:FRMI)
Upside Potential as of December 15, 2025: 249.24%
On December 15, Nicholas Amicucci, an analyst at Evercore ISI, reaffirmed a ‘Buy’ rating on Fermi Inc. (NASDAQ:FRMI), with an unchanged price target of $20, which reflects an upside potential of roughly 133% from the current price.
Earlier on December 5, Fermi Inc. (NASDAQ:FRMI) announced an Electric Service Agreement with Southwestern Public Service Company (SPS), a subsidiary of Xcel Energy. Under the agreement, SPS will deliver up to 200 megawatts of electrical capacity to Fermi’s Project Matador Campus through its high-voltage 115-kilovolt transmission system. While SPS will start providing 86 megawatts of electrical capacity in January 2026, it plans to increase the capacity to 200 megawatts.
The power is poised to strengthen Fermi Inc. (NASDAQ:FRMI)’s 11-gigawatt Project Matador Campus in Amarillo, which is already being built for hyperscale AI and computing operations. As stated by Larry Kellerman, its Chief Power Officer,
“Securing reliable and cost-effective power from Xcel Energy today and working together with them to grow our relationship over time is a key component of Fermi’s plans.”
Overall, Fermi Inc. (NASDAQ: FRMI) is a consensus buy among all nine analysts covering the stock. With a price target range of $20 to $39.20, the median target of $30 implies 249.24% upside.
Fermi Inc. (NASDAQ:FRMI) is a Texas-based energy development company specializing in next-generation electric grids. Founded on January 10, 2025, the company is committed to powering the AI needs of tomorrow.
1. ImmunityBio, Inc. (NASDAQ:IBRX)
Upside Potential as of December 15, 2025: 260.36%
On December 15, Edward Tenthoff, an analyst at Piper Sandler, maintained a ‘Buy’ rating on ImmunityBio, Inc. (NASDAQ:IBRX), keeping a price target of $5, which suggests an upside potential of 125.23% from the current level.
Three days earlier, Jefferies lifted the price target on ImmunityBio, Inc. (NASDAQ:IBRX) to $9 from $8, reiterating a ‘Buy’ rating on the stock. This upward revision to the price target, reflecting over 250% upside potential, follows the European Medicines Agency’s (EMA) recommendation to grant conditional marketing authorization for Anktiva in NMIBC-CIS. This builds on the existing approvals in the United States and the United Kingdom.
According to TheFly, Jefferies analysts believe ImmunityBio, Inc. (NASDAQ:IBRX) is executing its plans smoothly to expand its geographic and commercial presence, while advancing its pipeline. As the company engages in regulatory dialogue on papillary disease, with the NCCN guideline decision forthcoming, the BCG-naive data in the latter half of next year could present “another label expansion opportunity,” Jefferies notes.
Overall, ImmunityBio, Inc. (NASDAQ:IBRX) is a consensus buy among all five analysts covering the stock. With price targets ranging from $5 to $24, the median target of $8 implies 260.36% upside.
ImmunityBio, Inc. (NASDAQ:IBRX) is a California-based commercial-stage biotechnology company specializing in therapies to combat cancers and infectious diseases. Founded in 2014, the company has a mission to “harness the body’s own immune system.”
While we acknowledge the potential of IBRX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IBRX and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
